Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status Prescription; Discontinued
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 25000-012; 70121-1036; 65862-938; 68382-331; 68513-1054; 25000-014; 66499-0019; 0409-1008; 63629-2452; 69452-145; 17478-033; 25000-017; 10888-8103; 0143-9625; 67457-692; 70121-1035; 49483-687; 43598-563; 55150-213; 48943-0033; 58032-1001; 55111-663; 70121-1034; 69452-146; 65862-937; 55150-214; 68382-330; 0143-9624; 11014-0053; 43598-564; 43598-565; 43598-562; 0074-9036; 55111-665; 63629-2453; 0074-1658; 55150-212; 10888-8102; 55150-215; 65162-822; 58272-192; 49483-689; 0409-1007; 65162-824; 49483-688; 65162-823; 55111-664; 69452-147; 11014-0048; 16729-310; 0074-9037; 16729-311; 70121-1033; 67457-380; 65862-936; 10888-8104; 0143-9596; 0074-4637; 14474-021
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abscess11.01.08.0010.013489%Not Available
Acne23.02.01.001--Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.035189%Not Available
Acute pulmonary oedema02.05.02.004; 22.01.03.0050.025806%Not Available
Ageusia07.14.03.003; 17.02.07.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Aortic valve stenosis02.07.03.0040.002346%Not Available
Arrhythmia02.03.02.001--Not Available
Arteriovenous fistula thrombosis12.02.01.006; 24.01.01.0170.013489%Not Available
Arteriovenous fistula24.03.03.0010.002346%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Ascites02.05.04.002; 07.07.01.001; 09.01.05.003--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Atrial fibrillation02.03.03.002--
Atrial flutter02.03.03.003--
Atrioventricular block complete02.03.01.003--
Azotaemia20.01.01.0010.010557%Not Available
Back pain15.03.04.005--
Bacteraemia11.01.11.0010.003519%
Bladder cancer16.08.01.001; 20.03.04.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 12 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene